Purpose: We systematically reviewed preclinical and clinical studies on bladder chemodenervation with onabotulinumtoxin A to highlight current limitations and future drug delivery approaches. Materials and Methods: We identified peer reviewed basic and clinical research studies of onabotulinumtoxin A in the treatment of neurogenic bladder and refractory idiopathic overactive bladder published between March 2000 and March 2016. Paired investigators independently screened 125 English language articles to identify controlled studies on onabotulinumtoxin A administration in the MEDLINEÒ database and abstracts presented at annual American Urological Association meetings. The review yielded an evidence base of more than 50 articles relevant to the approach of injection-free onabotulinumtoxin A chemodenervation. Results: The efficacy and safety of intradetrusor injection of onabotulinumtoxin A for the treatment of overactive bladder are sensitive to injection volume and depth, and this issue has motivated researchers to study injection-free modes of drug delivery into the bladder. Urothelial denudation with protamine sulfate or dimethyl sulfoxide, liposome encapsulated onabotulinumtoxin A and other physical approaches are being studied to increase toxin permeability and avoid intradetrusor injections. Liposome encapsulated onabotulinumtoxin A enhances toxin activity while reducing its toxin degradation. The safety and efficacy of liposome encapsulated onabotulinumtoxin A were tested in a multicenter, placebo controlled study. Although this treatment successfully reduced urinary frequency and urgency, it did not significantly reduce urgency urinary incontinence episodes. Conclusions: Intradetrusor injection of onabotulinumtoxin A is a safe and effective treatment as reported in several large multicenter, randomized Accepted for publication August 4, 2016. No direct or indirect commercial incentive associated with publishing this article. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
controlled trials. Injection of the toxin into the bladder wall impairs afferent and efferent nerves, but injection-free drug delivery approaches only impair the bladder afferent nerves. Further studies are needed to develop better drug delivery platforms that overcome the drawbacks of intradetrusor injection, increase patient acceptance and reduce treatment costs.
Key Words: nerve block, botulinum toxins, liposomes, hydrogel, peptides OVERACTIVE bladder is defined by the International Continence Society as urinary urgency, with or without urgency urinary incontinence, usually accompanied by urinary frequency and nocturia. The etiology of OAB is thought to be multifactorial, and the factors involved are myogenic, neurogenic and/or integrative (trigger mediated). Although currently available antimuscarinics are the standard of care for OAB, long-term compliance is limited by minimal efficacy and poor tolerability from dry mouth and constipation. Antimuscarinics are also associated with drug tolerance and dysuria, both of which compromise patient adherence to these drugs. Newer treatments such as oral mirabegron, neuromodulation and chemodenervation have been embraced by many patients with OAB.
Bladder chemodenervation with neurotoxins seeks to target the neurogenic factors that contribute to the pathophysiology of OAB by blocking the release of neurotransmitters from bladder afferent and efferent nerves. Chemodenervation via intradetrusor injection of onabotulinumtoxin A is a FDA approved treatment for NDO and refractory OAB. Bladder onaBoNT-A has been found safe and effective in several large multicenter, randomized controlled trials. This review is focused on the promise of improving drug delivery with the development of injection-free approaches for bladder chemodenervation (see table) .
NEURONAL CONTROL OF MICTURITION
The micturition process involves urine storage and voiding. The neuronal control of micturition relies heavily on intact afferent transmission from the bladder to the brain followed by efferent transmission from the brain back to the bladder and urethral sphincter. 1 Parasympathetic nerves release acetylcholine during the voiding phase.
Norepinephrine released by sympathetic nerves innervating the bladder induces relaxation via b-adrenoceptors during the storage phase. Antimuscarinics suppress detrusor smooth muscle activity and inhibit detrusor overactivity. However, urinary urgency and frequency, which are both alleviated by antimuscarinics, are bladder storage symptoms. Because parasympathetic activity is usually absent during bladder storage, antimuscarinics work to improve these symptoms by acting on afferents found in the urothelium. 2 
PATHOLOGICAL AND THERAPEUTIC BLADDER DENERVATION
Neuronal control of micturition makes it highly susceptible to the injuries affecting neuronal pathways.
3 Therefore, the dysfunctional voiding that results from neurologic injury justifies denervation using surgical or pharmacological approaches. Surgical denervation involves transection of the nerve roots innervating the bladder. In contrast, pharmacological denervation or chemodenervation uses neurotoxins to disrupt efferent and afferent neurotransmission by inhibiting neurotransmitter release. Rhizotomy involves transection of the sacral nerve roots to the external urethral sphincter, thereby preventing detrusor dyssynergia. However, rhizotomy results in the loss of reflexive erectile function, vaginal lubrication and pelvic floor muscle strength. 4 Therefore, chemodenervation, which does not affect these functions, is more widely used.
Bladder chemodenervation impairs neurotransmitter release from afferent and efferent nerves. The neurotransmitters involved in the neural control of micturition include acetylcholine, norepinephrine, dopamine, serotonin, excitatory and inhibitory amino acids, adenosine triphosphate, 
MECHANISM OF ACTION
OnaBoNT-A is composed of 2 subunits, namely a 50 kDa light chain and a 100 kDa heavy chain. The light chain is the catalytic moiety of the toxin. After injection the heavy chain of onaBoNT-A binds with high affinity receptors called synaptic vesicle proteins type 2 expressed on neurons.
11 Recently the transcript for synaptic vesicle proteins type 2 was demonstrated in human urothelium cells. OnaBoNT-A inhibits the exocytosis of neurotransmitters from nerve terminals. The translocation of the onaBoNT-A light chain A into the neuron is dependent on the integration of the heavy chain into the membrane bilayer.
12
OnaBoNT-A prevents the exocytosis of acetylcholine into the synapse by proteolytic cleavage of synaptosomal-associated protein of 25 kDa (SNAP-25), an integral part of the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex. The cleavage of SNAP-25 by onaBoNT-A blocks the neuroexocytosis of neurotransmitters 13 and neurotrophins, 14 both of which are essential for micturition. 15 Therefore, cleavage of SNAP-25 is studied as a surrogate of onaBoNT-A treatment efficacy. The inhibitory effect of onaBoNT-A on the nerve evoked release of acetylcholine is only demonstrated after its injection into the bladder wall 13 and is not observed after topical application onto the bladder. 16 Reduction of detrusor contractility by onaBoNT-A is critically dependent on its reaching the neuronal sites responsible for exocytosis of acetylcholine. Recent studies demonstrate that apart from neuronal release, onaBoNT-A can also block the nonneuronal release of acetylcholine from the urothelium, 17 and this is relevant to understanding the action of onaBoNT-A instilled in the bladder. A recent study using guinea pig bladder revealed that the number of SNAP-25 positive neuronal fibers was directly proportional to the injection volume at a constant dose of the toxin.
18

CLINICAL EFFICACY OF INTRADETRUSOR INJECTION
Nitti et al reported on the long-term efficacy of intradetrusor onaBoNT-A in patients with idiopathic OAB during 3.5 years.
19 Patients treated with onaBoNT-A saw reductions from baseline in UUI by 3.1 to 3.8 episodes per day across 6 treatments.
20 UTI was the most common adverse event, and the risk of de novo urinary retention requiring clean intermittent catheterization after the first treatment was 4%, which was higher than in the placebo arms. Median duration of effect was 7.6 months and durable quality of life improvements were seen during the 3.5 years. Treated patients with neurogenic OAB showed significant improvement in bladder storage symptoms with a similar increase in maximum cystometric capacity of 157 and 157.2 cc at 6-week followup after 200 and 300 IU onaBoNT-A, respectively. 21 Investigators found a lack of dose dependent increase in efficacy, and UTI was noted in 27.6% and 30.8% of patients treated with 200 and 300 IU onaBoNT-A, respectively. 20 The frequency of adverse outcomes increases with higher and repeated doses of onaBoNT-A. 15 A recent retrospective study of onaBoNT-A treatment in patients with nonneurogenic, refractory OAB showed that the incidence of urinary retention was 35%. 22 Mean age of the 160 patients studied was 64 years and 24% of the patients were men. These authors found that urinary retention was associated with an increased preoperative post-void residual. Urinary retention is also associated with the need to initiate clean intermittent catheterization and bacteriuria.
INJECTION TECHNIQUE
There remains no consensus on the ideal template for injecting onaBoNT-A into the bladder. A randomized trial of 45 patients evaluated the effectiveness of onaBoNT-A injections into the suburothelium, bladder body and bladder base. 23 The authors found that bladder body injections were the most effective, followed by suburothelial and bladder base injections. A subsequent meta-analysis of patients with OAB revealed no significant differences in efficacy between trigonal sparing and nontrigonal sparing injection techniques with short-term cure rates of 52.9% and 56.9%, respectively. 24 The incidence of postoperative urinary retention for trigonal and extratrigonal injection was 4.2% and 3.7%, respectively, and the incidence of UTI in the respective groups was 7.5% vs 21.0%.
Studies on guinea pig bladders showed that the potency of intradetrusor onaBoNT-A injection is sensitive to injection volume and depth.
18 Furthermore, the different onaBoNT-A formulations may not diffuse the same way into the bladder wall because of variability in protein size, product format and pharmacological properties. Dosing of botulinum toxin as measured in units is not interchangeable between the different preparations. Furthermore, high quality studies are needed to determine the optimal dosing and long-term application. Off label uses of onaBoNT-A in urology include detrusor external sphincter dyssynergia and IC/BPS.
The extent of tissue spread after injection may impact the risk of adverse events including urinary retention and recurrent UTIs. Concerns with the present injection technique include leakage of toxin outside the bladder, hematuria, pain and uneven toxin distribution. MRI represents a powerful, noninvasive tool to track the spread of paramagnetic substances. However, onaBoNT-A is not paramagnetic and its spread cannot be directly detected by MRI. Several human studies have reported mixing onaBoNT-A with gadolinium based contrast agents of different polarity, osmolarity and chemical structure. 25, 26 Mehnert et al injected a mixture of onaBoNT-A 300 U diluted in 27 ml 0.9% saline and 3 ml Magnevist (a linear charged gadolinium chelate) into 6 patients with neurogenic bladder. 26 This mixture was injected into 30 sites in 3 patients and 10 sites in 3 patients. Pelvic MRI was performed immediately after the injections. Overall 82.4% of the total injected volume was found in the detrusor, regardless of the number of injection sites. The remaining 17.6% was found in the lateral extraperitoneal fat tissue adjacent to the bladder dome.
Alsinnawi et al injected onaBoNT-A with a macrocyclic uncharged gadolinium chelate. 25 OnaBoNT-A dosed at 100 or 200 U was reconstituted with 19 ml 0.9% saline and 1 ml Gadovist into idiopathic overactive bladders or neurogenic bladders, respectively. Twenty patients received 20 injections of intradetrusor onaBoNT-A, including 2 injections into the trigone. The depth of each injection was 2 mm. MRI performed 3 hours after injection found injected contrast in the bladder wall of 18 patients and extravesical extravasation was noted in 80% of the patients.
Existing evidence regarding the risk of tissue spread of onaBoNT-A outside of the bladder remains insufficient and further studies are necessary. MRI studies involve an erroneous assumption about the similarity in the migration of the contrast agent and the toxin outside the bladder. Nevertheless, studying injected contrast agents of different polarity and structure does shed light on the migration of onaBoNT-A injected into the bladder.
INJECTION-FREE CHEMODENERVATION
There has been increased interest in developing injection-free delivery of onaBoNT-A into the bladder. Instillation of onaBoNT-A reconstituted with saline into the bladder lumen was ineffective in animal studies.
27,28 Intraluminal onaBoNT-A instillation without injection failed perhaps because of toxin degradation by urine proteases, toxin dilution by urine at instillation and poor uptake of onaBoNT-A (a large macromolecule) across the urothelium (see figure) .
The molecular weight of onaBoNT-A is 150 kDa and this large size is the major impediment in its uptake into the bladder wall. Urothelial denudation by protamine sulfate and organic solvents has been assessed to increase onaBoNT-A uptake into the bladder wall.
Dimethyl Sulfoxide DMSO is an organic solvent that has been used to facilitate the delivery of several anticancer drugs into animal bladders. 29 A study of the effects of DMSO on pig bladders demonstrated histological changes in the urothelium that increased the permeability of instilled agents. 30 Another study used female rats that received 10 U intravesical onaBoNT-A in saline or in DMSO for a 2-hour period. 28 Subsequently the rats were infused with 0.25% acetic acid for 1 hour at 1 or 4 weeks after onaBoNT-A instillation. The group instilled with onaBoNT-A in DMSO showed protection against acetic acid induced bladder irritation. Furthermore, increases in SNAP-25 cleavage and transcript levels of calcitonin gene-related peptide were only seen at 1 week in the rats that received onaBoNT-A in DMSO.
DMSO and OnaBoNT-A Regulatory approval of DMSO and onaBoNT-A reduces the burden of clinical testing of this combination. Petrou et al studied 25 women with idiopathic detrusor overactivity refractory to antimuscarinics who were given onaBoNT-A mixed with DMSO. 30 OnaBoNT-A 300 U mixed with 50 ml of 50% DMSO were given to 22 patients and two-thirds of that dose was given to 3 patients. Efficacy and toxicity were assessed at baseline, and at 1 and 3 months after treatment with 24-hour pad weights, voiding diaries and post-void residual. In addition, patients completed the Incontinence Impact Questionnaire-short form (IIQ-7) and the Urogenital Distress Inventory (UDI-6) questionnaire. Median number of UUI episodes decreased from 4 at baseline to 2 at 1 month (p¼0.004) and then returned to 4 at 3 months. A significant reduction in symptom scores from baseline was also noted. The IIQ-7 improved from 13 to 7 at 1 month (p¼0.007) and the UDI-6 improved from 10 to 5 at 1 month (p¼0.003). No serious AEs or urinary retention were noted.
Protamine and Protein Transduction Domains
Protamine is an arginine-rich polycationic peptide with a molecular weight of 5.1 kDa. Protamine is used as an antidote to heparin overdoses and as a complexing agent for long-acting insulin. Protamine internalizes into cells through heparin sulfate mediated endocytosis. 31 Several studies have noted that protamine instillation at concentrations of 10 to 30 mg/ml denudes the urothelium. 32 This effect on the urothelium was used to enhance the uptake of onaBoNT-A into the bladders of spinal cord injured rats. 27 The efficacy of onaBoNT-A was only detectable in rats pretreated with protamine sulfate, suggesting that onaBoNT-A cannot cross the intact urothelium.
Protamine belongs to a family of cationic peptides that cross membranes through protein transduction. Small sections of these proteins (10 to 16 residues long) are responsible for protein transduction domains. 33 PTDs facilitate the transport of fused materials across cellular membranes through an energy dependent endocytosis, macropinocytosis and direct membrane translocation. 31 In contrast to the sequential addition of protamine and onaBoNT-A into the bladder, 27 PTDs can also be linked covalently to onaBoNT-A to facilitate its entry into any cell type independent of receptors and transporters.
PTDs are recognized as promising vehicles for the delivery of macromolecules. PTDs are categorized into the 2 types of polycationic and amphipathic. TAT peptide is a PTD derived from HIV which has opened the door for macromolecule delivery Schematic illustration of different approaches attempted for intravesical delivery of botulinum toxin. Intradetrusor injection of native toxin can chemodenervate efferent and afferent arm of micturition reflex of OAB. Liposome (LP) based intravesical delivery of botulinum toxin can only chemodenervate afferent arm of micturition reflex. Botulinum toxin has been conjugated with cationic peptide and complexed with thermosensitive hydrogel for improved delivery of toxin.
across the urothelium. In 1991 Mann and Frankel demonstrated that the basic domain of TAT encompassing amino acids 38-58 retained the transducing ability. This 11-amino acid peptide fragment of the TAT protein basic domain of TAT has been used in the cellular uptake of proteins, oligonucleotides and nanoparticles. TAT binding to cellular membranes is mediated through charge interaction between the basic region of TAT and charged polysaccharides.
We previously reported on the successful uptake of peptide nucleic acids conjugated with the TAT peptide into rat bladders. 34 As such, successful intravesical delivery of onaBoNT-A into the bladder wall was thought possible and can be easily envisioned following conjugation with TAT peptide. Recently the successful transdermal delivery of onaBoNT-A conjugated to PTDs was reported. 35 This approach, developed by Revance Therapeutics as a gel application, reduced skin wrinkles in 45 patients by 44.5%. As will be discussed, topical gel administration into the bladder is another injectionfree approach for chemodenervation. 36 
LIPOSOMES
Liposomes (lipid vesicles) have been extensively studied as a drug delivery platform for anticancer drugs and several such products have received FDA approval. Liposomes have also been studied as toxin carriers to enhance efficacy at lower doses. Liposomes rely on vesicle endocytosis for intravesical drug delivery. In contrast to DMSO or 10% ethanol, liposomes do not compromise bladder permeability. Empty liposomes composed of endogenous lipids have been reported to have a therapeutic effect in interstitial cystitis. 37 Ultrastructural and confocal microscopy of cultured urothelial cells showed that the bladder uptake mechanism of fluorescent liposomes is endocytosis 38 which is energy dependent. 39 The cellular uptake of electron dense gold encapsulated liposomes was found to be temperature dependent, indicating a role for energy dependent endocytosis in the uptake of liposomes. 38, 40 Our group has also reported on the use of liposomes for the intravesical delivery of capsaicin 40 and onabotulinumtoxin A. 41 
Reversible Complexation of Liposomes and Botulinum Toxin
The lipid bilayer of liposomes was used as a cell membrane model for understanding the translocation of the light chain of onaBoNT-A.
12, 42 The secondary structure of onaBoNT-A after its interaction with liposomes was analyzed using circular dichroism and Fourier transform infrared spectroscopy at different pH values. Heavy and light chains of onaBoNT-A induce a partially reversible aggregation of liposomes at a pH of 4 and then integrate into the lipid bilayer. 12 The pH dependent aggregation and endocytosis of onaBoNT-A by liposomes are possible because the pH of the endocytic vesicles is 4. Denaturation studies of the heavy chain of onaBoNT-A indicate major structural reorganization on its interaction with cell membranes at low pH. This aggregation of onaBoNT-A with liposomes is reversible, allowing the toxin to be available for enzymatic action at a pH of 7 in the cytosol.
Enzymatic Activity of Liposome Bound Toxin
Caccin et al studied the enzymatic activity of onaBoNT-A complexed with liposomes in the cleavage of a SNARE protein called vesicle associated membrane protein. 42 Binding of the toxin to lipid membranes enhanced the actions of onaBoNT-A as well as tetanus toxin.
Proteolytic Degradation of OnaBoNT-A
Since direct instillation of onaBoNT-A into the bladder exposes it to urine proteases, it is likely that the reduced potency of instilled onaBoNT-A vs intradetrusor injection is due to proteolytic degradation of the toxin. Therefore, it is relevant to examine the protection afforded by complexing the toxin to liposomes. A recent study evaluated the degradation of onaBoNT-A bound to liposomes. 43 OnaBoNT-A with or without liposomes was exposed to pepsin and then put through gel electrophoresis to assess toxin cleavage. Peptide bands were then excised, digested with trypsin and extracted for mass spectrometry. Electrophoresis and mass spectrometry analysis confirmed that liposomes protected the toxin from pepsin cleavage with the formation of oligomeric membrane associated intermediates. Fluorescence experiments suggested that amino acid residues within the heavy chain of the toxin move to a hydrophobic environment upon association with liposomes. The reduced proteolytic degradation of onaBoNT-A complexed with liposomes seen in vitro resulted in further testing.
Testing OnaBoNT-A Complexed with Liposomes in Animal Models
The instillation of onaBoNT-A complexed with liposomes into rat bladders significantly reduced bladder overactivity caused by acetic acid. 41 One week after instillation the group treated with onaBoNT-A complexed with liposomes showed increased voided volumes compared to controls. The duration of the onaBoNT-A effect was similar to that reported with DMSO. 43 
Clinical Experience of OnaBoNT-A Complexed with Liposomes
A multicenter, placebo controlled study to assess the safety and efficacy of onaBoNT-A complexed with liposomes was performed in men and women with OAB. 44, 45 This treatment successfully reduced urinary frequency and urgency. However, the treatment did not reduce UUI episodes. Furthermore, onaBoNT-A complexed with liposomes did not result in urinary retention. The risk of UTI was similar between placebo and treatment arms. It can be inferred that instillation of onaBoNT-A complexed with liposomes successfully impairs afferent neurotransmission but not efferent neurotransmission in the bladder.
THERMOSENSITIVE HYDROGEL
Several investigators have studied intravesical thermosensitive hydrogels to increase the time of drugs in the bladder. 36, 46 The hydrogel is formed by an aqueous solution of a polymer which exhibits temperature dependent nonNewtonian fluid behavior. The unique rheological property of the hydrogel allows the instillation to be liquid at a room temperature of 25C and then it becomes semisolid at body temperature. 36 In our earlier study we modified the biodegradable triblock polymer Poly(ethylene glycol)-Poly [lactic acid-co-glycolic acid]-Poly(ethylene glycol) for bladder instillation. 36 The understood mechanism of temperature sensitive gelation at 37C is micelle packing with an increase in micelle volume fraction. However, lower micelle volume fraction at 25C makes it a free flowing liquid. In our study we showed that intravesical thermosensitive hydrogel extended the time of a fluorescent probe in the bladder. 36 A recent clinical study from Urogen (previously Theracoat) reported that thermosensitive hydrogel could improve the intravesical delivery of onaBoNT-A in 15 patients with IC/BPS). 47 That study reported that hydrogels in the bladder allowed a gradual release of 200 U onaBoNT-A for up to 6 to 8 hours, well beyond the typical 2 hours for saline instillation. Validated Interstitial Cystitis Symptom Problem Index and visual analog score were collected at baseline and at 12 weeks. One severe AE of benign submandibular lymphadenopathy was reported which was preexisting. Three cases of mild constipation after instillation were noted as possible drug related AEs. Nonrelated AEs included flu and worsening depression symptoms. 47 Urogen is currently pursuing clinical testing of their hydrogel and onaBoNT-A product in Europe. A potential safety concern of hydrogels placed in the bladder is possible urinary retention from obstruction to urine flow.
PHYSICAL APPROACHES Iontophoresis
The increasing use of onaBoNT-A as a treatment for detrusor overactivity in children has motivated the search for injection-free administration. EMF is a physical approach of increasing bladder permeability similar to the chemical means seen with protamine and DMSO. EMF involves the placement of 1 electrode inside the bladder and 1 outside on the abdomen to create a potential difference to drive the diffusion of instilled drugs into the bladder.
A total of 15 children (mean age 7.8 years) with NDO from myelomeningocele were studied with this approach. 48 OnaBoNT-A 10 U/kg was inserted into the bladder through a catheter with a pulsed current generator that delivered 10 mA for 15 minutes. Urodynamic parameters measured included maximal bladder capacity and maximal detrusor pressure. In addition, vesicoureteral reflux grading was evaluated before treatment, and at 1, 4 and 9 months after treatment. The combination of intravesical onaBoNT-A and iontophoresis improved vesicoureteral reflux grade and bladder capacity. AEs included skin erythema and dysuria in 6 subjects.
Low Energy Shock Wave
This method involves the delivery of shock waves to the target organ for increasing cell permeability. The use of low energy shock waves for intravesical drug delivery is predicated on reports of an increase in tissue permeability after shock wave application with increased drug delivery to the cells. Kodama et al suggested that shock waves could cause shear forces generated from the movement of liquid relative to cells, thereby increasing the permeability of the plasma membrane. 49 Shock waves can deliver molecules of up to 2,000,000 molecular weight inside the cell. We recently reported that onaBoNT-A delivered into rat bladders using low energy shock wave reduced inflammation, reduced SNAP-23 and 25, and increased voided volumes. 50 
CONCLUSIONS
OnaBoNT-A is a large macromolecule and the urothelium impedes its easy delivery into the bladder wall. Success in animal models was seen with intravesical onaBoNT-A administration after urothelial denudation by protamine sulfate. In addition, DMSO has been used to facilitate onaBoNT-A penetration into the bladder, thereby demonstrating clinical efficacy. Biochemical studies have shown that onaBoNT-A complexed with liposomes prevents proteolytic degradation of the toxin to enhance its efficacy. Liposomes have been extensively researched as a platform for delivering neurotoxins including onaBoNT-A. Liposomes complexed with onaBoNT-A show promise in clinical studies on patients with OAB, reducing urinary frequency and urgency and resulting in no urinary retention. Novel approaches to the injection-free delivery of onaBoNT-A have so far not demonstrated efficacy comparable to that of intradetrusor injection. However, continued research with a variety of approaches shows great promise. 
